ArticleNeurology2026
Differences in Survival Associated With the First Antiseizure Medication in People With Dementia and Epilepsy.
Article in Neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectiveEpilepsy is an increasingly recognized comorbidity in neurocognitive disorders. Although experts recommend newer antiseizure medications (ASMs), whether there are real-world benefits of selecting particular ASMs for epilepsy in dementia remains unknown. Our objective was to examine whether different ASMs are associated with differences in survival in persons with epilepsy and dementia.
methodsA cohort study was conducted using Swedish national registers. We included individuals with dementia who received ASM treatment after a diagnosis of epilepsy after January 1, 2006. Data were analyzed until December 2023. Dispensed ASMs (Anatomical Therapeutic Code N03) were used to identify treatment; patients were categorized as starting one of the 4 most common ASMs (carbamazepine, levetiracetam, lamotrigine, valproate) or other ASMs. Recurrent prescriptions were used to determine treatment duration. Associations between all-cause death and ASMs were assessed by Cox proportional hazards regression. We also assessed causes of death and the risk of cardiovascular death.
resultsIn Sweden, between 2006 and 2023, we included 5,764 individuals (2,811 men [48.8%] and 2,953 women [51.2%]) using their first ASM after a diagnosis of epilepsy and dementia. Carbamazepine (n = 1,578) was the most common ASM before 2015 and levetiracetam (n = 2098) most common thereafter. In Kaplan-Meier analyses and Cox regression models adjusting for age, sex, year of ASM start, and comorbidities, valproate (n = 746) was associated with increased adjusted hazard ratio (aHR) of death (1.34, 95% CI 1.20-1.48), in contrast to lamotrigine (n = 922, aHR: 0.84, 95% CI 0.75-0.93) and levetiracetam (n = 2098, aHR: 0.93, 95% CI 0.85-1.03). The risks were similar in analyses using restricted mean survival time, propensity score-matched sets of participants, balancing weights in regression models, and cases with epilepsy onset in existing dementia. Cardiovascular causes of death were more common among users of valproate or carbamazepine than among users of lamotrigine and levetiracetam. Compared with carbamazepine, valproate was associated with increased risk of cardiovascular death (aHR: 1.30; 95% CI 1.11-1.52) while lamotrigine (aHR 0.79; 95% CI 0.66-0.94) was associated with a reduced risk. DISCUSSION: In this population-wide cohort study, use of valproate was associated with the highest risk of death in persons with epilepsy and dementia. Lamotrigine and, in some models, levetiracetam were associated with better survival than both valproate and carbamazepine. This provides real-world support for existing expert guidelines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.